Herpes Simplex Virus Treatment Market To Benefit from Increased Global Uptake of 2024 By 2030

 Herpes Simplex Virus Treatment Market Growth & Trends

The global herpes simplex virus treatment market size is expected to reach USD 4.08 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 8.1% from 2024 to 2030. The growth of the market is attributed to factors such as increasing prevalence of herpes infection among the population, growing awareness about the disease globally, rising geriatric and immunocompromised population, and an increasing demand to develop novel treatment options to meet the demand for herpes infection therapeutics. Moreover, public-private initiatives are further expected to fuel the growth of the market.

According to the WHO, in 2020, nearly 491.5 million people were suffering from genital herpes caused by the herpes simplex virus 2, and several billion people have herpes simplex virus 1 infection. Although the infection is typically asymptomatic, those who have it are capable of easily transmitting the virus to another person through contact. Furthermore, nearly 80 percent of the global population is a carrier of herpes. This is creating an opportunity for the growth of herpes infection treatment drugs.

Research initiatives and increasing collaborations between research organizations are facilitating the development of novel treatment alternatives against viruses, which is anticipated to boost market growth. In January 2020, a research collaboration between scientists from the EPFL in Lausanne, Switzerland, the University of Geneva (UNIGE), and the University of Manchester led to the development of novel antiviral materials, virucides, made from sugar that show promise for the treatment of herpes simplex (cold sore virus). The development of virucides from sugar has facilitated the arrival of an innovative antiviral drug, which aids treatment without being toxic to humans.

Key players operating in the market are focusing on developing novel and innovative products to meet the increasing demand for providing effective therapeutics. With the increasing demand for effective therapeutics, companies are engaged in developing novel and innovative medicines against infection. For instance, in July 2021, a Phase III study of pritelivir, a novel drug by AiCuris Anti-infective Cures AG, which is a German pharmaceutical company, was commenced, post receiving encouraging Phase II interim results from the Phase II/III trial. This leading compound is developed to treat immunocompromised patients with mucocutaneous HSV infections that are acyclovir-resistant. It was granted Breakthrough Therapy Designation by the U.S. FDA in June 2020. The regulatory support for innovative therapies is projected to improve the number of new drugs entering the market, facilitating enhanced treatment rates, and thereby accelerating market growth. 

Request a free sample copy or view report summary: Herpes Simplex Virus Treatment Market Report

Herpes Simplex Virus Treatment Market Report Highlights

• By treatment, the HSV-1 segment held the largest share in 2023 owing to the high prevalence of infection
• By drug, the acyclovir segment is expected to grow at the fastest rate during the forecast period due to the effectiveness and availability of acyclovir as an oral and topical formulation
• By vaccine, the simplirix segment is expected to grow at the fastest rate during the forecast period as it is the only vaccine available showing promising results as a vaccine candidate
• North America dominated the global market in 2023 owing to the increasing awareness regarding STDs and the rise in healthcare expenditure

Access Press Release@ https://www.grandviewresearch.com/press-release/global-herpes-simplex-virus-treatment-market

Herpes Simplex Virus Treatment Market Segmentation

Grand View Research has segmented the global herpes simplex virus treatment market based on type, drug, vaccine, route of administration, end-use, and region:

Herpes Simplex Virus Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)

• Herpes Simplex Virus-1 (HSV-1)
• Herpes simplex virus-2 (HSV-2)

Herpes Simplex Virus Treatment Drug Outlook (Revenue, USD Million, 2018 - 2030)

• Acyclovir
• Valacyclovir
• Famciclovir
• Other Drugs

Herpes Simplex Virus Treatment Vaccine Outlook (Revenue, USD Million, 2018 - 2030)

• Simplirix
• Others

Herpes Simplex Virus Treatment Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral
• Injectable
• Topical

Herpes Simplex Virus Treatment End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Herpes Simplex Virus Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • US.
  • Canada
• Europe
  • Germany
  • UK.
  • France
  • Italy
  • Spain
  • Norway
  • Sweden
  • Denmark
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

List of Key Players in Herpes Simplex Virus (HSV) Treatment Market

• GSK plc
• Emcure Pharmaceuticals Ltd.
• Carlsbad Tech
• Glenmark Pharmaceuticals Inc.
• Viatris, Inc.
• Fresenius Kabi AG
• Teva Pharmaceuticals Industries Ltd.
• Apotex Inc.
• Sanofi
• Novartis AG

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.